Condition
Central Serous Chorioretinopathy (CSC)
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Withdrawn1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07347119Not Yet RecruitingPrimary
Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients
NCT01256580Not ApplicableWithdrawn
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Showing all 2 trials